Effectiveness of deferred therapy with ganciclovir in renal allograft recipients with cytomegalovirus disease.
Waiser
J
J
Department of Internal Medicine-Nephrology, Charité, Humboldt-University, Berlin, Germany.
Budde
K
K
Schreiber
M
M
Korn
K
K
Stenglein
S
S
Drenckhahn
J T
JT
Böhler
T
T
Hauser
I
I
Neumayer
H H
HH
D000208:Acute Disease; D000998:Antiviral Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D003587:Cytomegalovirus / Q000302:isolation & purification; D003586:Cytomegalovirus Infections / Q000175:diagnosis / Q000188:drug therapy* / Q000453:epidemiology; D004334:Drug Administration Schedule; D005500:Follow-Up Studies; D015774:Ganciclovir / Q000008:administration & dosage / Q000627:therapeutic use*; D006084:Graft Rejection / Q000453:epidemiology; D006085:Graft Survival; D006801:Humans; D015994:Incidence; D016030:Kidney Transplantation / Q000276:immunology / Q000401:mortality / Q000502:physiology*; D016133:Polymerase Chain Reaction; D011183:Postoperative Complications; D012189:Retrospective Studies; D012307:Risk Factors; D015996:Survival Rate; D013997:Time Factors
D000998:Antiviral Agents; D015774:Ganciclovir